SynthesisAnnals of internal medicine2020
Pharmacotherapy for the Treatment of Cannabis Use Disorder: A Systematic Review.
Synthesis in Annals of internal medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Pharmacotherapies for cannabis use disorder.The Cochrane database of systematic reviews · 2025Pooled it
- Efficacy of cannabidiol alone or in combination with Δ-9-tetrahydrocannabinol for the management of substance use disorders: An umbrella review of the evidence.Addiction (Abingdon, England) · 2025Pooled it
- The effect of daily aerobic cycling exercise on cannabis withdrawal: An inpatient randomised controlled trial.Scientific reports · 2026Trial
- N-acetylcysteine for youth cannabis use disorder: randomized controlled trial main findings.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Trial
- Evaluating cannabis use risk reduction as an alternative clinical outcome for cannabis use disorder.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2022Trial
- Cannabis Use Disorder and Mortality Risk: A Matched Cohort Study from a Colorado Health System.Journal of general internal medicine · 2026Article
- Sex differences in stress responding in a randomized, placebo-controlled clinical trial of progesterone in cannabis use disorder.Psychopharmacology · 2026Article
- Beyond abstinence: Redefining success in cannabis use disorder treatment.Addiction (Abingdon, England) · 2026Article
- Associations between recreational cannabis legalization and cannabis use disorder treatment outcomes in California, 2010-2021.Journal of cannabis research · 2025Article
- Predictors of effective therapy among individuals with Cannabis Use Disorder: a review of the literature.European archives of psychiatry and clinical neuroscience · 2025Review
- Effectiveness of cannabis use and cannabis use disorder interventions: a European and international data synthesis.European archives of psychiatry and clinical neuroscience · 2025Review
- The potential of non-psychedelic 5-HT2A agents in the treatment of substance use disorders: a narrative review of the clinical literature.Expert opinion on pharmacotherapy · 2025Review
- A phase III multisite randomised controlled trial to compare the efficacy of cannabidiol to placebo in the treatment of cannabis use disorder: the CBD-CUD study protocol.BMC psychiatry · 2024Article
- Prevalence and Treatment of Substance Misuse in Older Adults: Beyond Early Adulthood.Substance abuse and rehabilitation · 2024Review
- Treatment of Adolescent Cannabis Use Disorders.The Psychiatric clinics of North America · 2023Review
- Sex differences in endocannabinoid tone in a pilot study of cannabis use disorder and acute cannabis abstinence.Addiction biology · 2023Article
- Association between cannabis use disorder symptom severity and probability of clinically-documented diagnosis and treatment in a primary care sample.Drug and alcohol dependence · 2023Observational
- Treatment of Adolescent Cannabis Use Disorders.Child and adolescent psychiatric clinics of North America · 2023Review
- Principles of care for pregnant and parenting people with substance use disorder: the obstetrician gynecologist perspective.Frontiers in pediatrics · 2023Review
- Management of Hyperhomocysteinemia, Low Vitamin Levels, and Low Cortisol in Cannabis Users: A Report of 2 Cases.Journal of chiropractic medicine · 2022Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Background: Cannabis use disorder (CUD) is a growing concern, and evidence-based data are needed to inform treatment options. Purpose: To review the benefits and risks of pharmacotherapies for the treatment of CUD. Data Sources: MEDLINE, PsycINFO, Cochrane Database of Systematic Reviews, and clinical trial registries from inception through September 2019. Study Selection: Pharmacotherapy trials of adults or adolescents with CUD that targeted cannabis abstinence or reduction, treatment retention, withdrawal symptoms, and other outcomes. Data Extraction: Data were abstracted by 1 investigator and confirmed by a second. Study quality was dually assessed, and strength of evidence (SOE) was determined by consensus according to standard criteria. Data Synthesis: Across 26 trials, the evidence was largely insufficient. Low-strength evidence was found that selective serotonin reuptake inhibitors (SSRIs) do not reduce cannabis use or improve treatment retention. Low- to moderate-strength evidence was found that buspirone does not improve outcomes and that cannabinoids do not increase abstinence rates (moderate SOE), reduce cannabis use (low SOE), or increase treatment retention (low SOE). Across all drug studies, no consistent evidence of increased harm was found. Limitations: Few methodologically rigorous trials have been done. Existing trials are hampered by small sample sizes, high attrition rates, and heterogeneity of concurrent interventions and outcomes assessment. Conclusion: Although data on pharmacologic interventions for CUD are scarce, evidence exists that several drug classes, including cannabinoids and SSRIs, are ineffective. Because of increasing access to and use of cannabis in the general population, along with a high prevalence of CUD among current cannabis users, an urgent need exists for more research to identify effective pharmacologic treatments. Primary Funding Source: U.S. Department of Veterans Affairs. (PROSPERO: CRD42018108064).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.